Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What Did Changing Sales Rep Compensation Do For GSK?

This article was originally published in Scrip

Executive Summary

Across the pharmaceutical industry there has been a lot of talk about improving reputation and building a "patient-centric" business model. GlaxoSmithKline wanted to put its money where its mouth is and prioritize patients by changing the way it compensated it sales reps. After a "bumpy road" the new model has worked well for both customers and for business as better sales calls with doctors drives new product growth, says Victoria Williams, GSK's vice president and sales director, France.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts